Hirudin-Like Factors
A multigene family of thrombin inhibitors with femtomolar affinity
Last updated: March 14, 2026
Mechanism Disclaimer
Hirudin is not a single molecule but a family of 20+ isoforms sharing approximately 20% inter-variant homology. Three principal variants — HV1, HV2, and HV3 — have been characterized from Hirudo medicinalis, each encoded by distinct gene loci. The 2020 genome sequencing confirmed a multigene family under diversifying selection (Kvist et al., 2020), consistent with the evolutionary pressure of host hemostatic adaptation.
Molecular Architecture
Primary Structure
65 amino acids, approximately 7 kDa. The molecule consists of two functional domains: an N-terminal globular domain stabilized by three disulfide bridges (Cys6-Cys14, Cys16-Cys28, Cys22-Cys39), and a C-terminal acidic tail (residues 49-65) bearing a post-translationally sulfated tyrosine at position 63 (Tyr63-SO3).
Bivalent Binding Mechanism
Hirudin simultaneously engages two thrombin sites: the N-terminal domain blocks the catalytic active site, while the C-terminal tail binds anion-binding exosite I (fibrinogen recognition site). This bridge-like bivalent interaction yields a Kd of 2 × 10⁻¹⁴ M (native, sulfated Tyr63) — the tightest non-covalent protein-protein interaction measured in nature.
Binding Affinity Comparison
Modern Genomic Findings
Multigene Family (2020)
Kvist et al. (2020) genome-wide analysis confirmed hirudin genes form a multigene family under positive diversifying selection, suggesting ongoing evolutionary optimization against vertebrate thrombin variants. Multiple paralogous loci encode structurally distinct isoforms.
Tandem-Hirudin (2022)
Hohmann et al. (2022) identified Tandem-Hirudin from Hirudinaria manillensis — the first oligomeric member of the hirudin superfamily. Despite structural homology, this variant shows no thrombin-inhibitory activity, suggesting functional divergence within the family.
Novel Recombinant (2025)
A 2025 recombinant hirudin variant achieved Ki = 0.323 nM, exceeding bivalirudin in thrombin inhibition potency. Advances in cell-free synthesis systems (Szatkowski et al., 2020) are enabling rapid prototyping of engineered variants.
Cell-Free Synthesis
Szatkowski et al. (2020) demonstrated successful cell-free protein synthesis of functional hirudin variants, bypassing traditional expression systems. This approach accelerates structure-activity relationship studies and enables rapid screening of engineered analogs.
Pharmaceutical Derivatives
| Drug | Hirudin Basis | FDA | Status | Indication |
|---|---|---|---|---|
| Lepirudin (Refludan) | HV1 (desulfatohirudin) | 1998 | Discontinued 2012 (low demand; known anaphylaxis risk) | HIT-associated thrombosis |
| Desirudin (Iprivask) | HV2 recombinant | 2003 | Active | DVT prophylaxis after hip replacement |
| Bivalirudin (Angiomax) | Hirudin C-terminal + D-Phe-Pro-Arg | 2000 | Active | PCI anticoagulation |
| Dabigatran (Pradaxa) | Hirudin SAR — oral peptidomimetic | 2010 | Active | Stroke prevention in atrial fibrillation |